<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02534688</url>
  </required_header>
  <id_info>
    <org_study_id>Kingchulalongkorn</org_study_id>
    <nct_id>NCT02534688</nct_id>
  </id_info>
  <brief_title>Effectiveness of Levonorgestrel-intrauterine System (LNG-IUS) Versus Depot Medroxyprogesterone Acetate (DMPA) in Treatment of Pelvic Pain in Clinically Diagnosed Endometriotic Patients</brief_title>
  <official_title>Effectiveness of Levonorgestrel-intrauterine System (LNG-IUS) Versus Depot Medroxyprogesterone Acetate (DMPA) in Treatment of Pelvic Pain in Clinically Diagnosed Endometriotic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Chulalongkorn Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Chulalongkorn Memorial Hospital</source>
  <brief_summary>
    <textblock>
      randomized controlled trial&#xD;
&#xD;
      Eligiblility criteria Provisional diagnosis Clinical presentation Progressive dysmenorrhea&#xD;
      Chronic pelvic pain Deep dyspareunia Evidences of endometriosis Endometriotic nodule&#xD;
      Cul-de-sac nodularity Endometrioma detected by ultrasonography size &lt; 4 cm&#xD;
&#xD;
      Inclusion criteria Female age 18-45 yr Moderate to severe pelvic pain categorized by VAS &gt;50&#xD;
      Previous sexual intercourse&#xD;
&#xD;
      Exclusion criteria Co-existing other genital tract disease associated pain Previous hormonal&#xD;
      use within 3 months History of DMPA treatment failure WHO eligibility criteria 2009 for DMPA&#xD;
      and LNG-IUS Category 3,4 Fertility desire in upcoming 1 year&#xD;
&#xD;
      Primary objective To compare efficacy of pain control in endometriosis associated pelvic pain&#xD;
      between LNG-IUS and DMPA&#xD;
&#xD;
      Secondary objective To compare side effect, continuation rate, satisfaction and quality of&#xD;
      life between LNG-IUS and DMPA in treatment of endometriosis associated pelvic pain&#xD;
&#xD;
      Primary outcome Severity of pelvic pain Measured by VAS score 0 mean no pain 100 mean most&#xD;
      pain&#xD;
&#xD;
      Secondary outcomes Vaginal bleeding pattern Side effects of systemic progestogen Lipid&#xD;
      profiles Weight gain Quality of life Measured by quesionaire SF36 Satisfaction Measrured by&#xD;
      linket scale 0-4 0 mean very dissatisfied 1 dissatisfied 2 not satisfied and dissatiffied 3&#xD;
      satisfied 4 very satisfied Continuation rate Endometrioma size reduction&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of pelvic pain : measured by visual analog scale</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life measured by Quesionaire SF 36 Thai version</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid profile : total cholesterol, triglyceride, LDL, HDL</measure>
    <time_frame>6months</time_frame>
    <description>Measured by blood collection in mg/dl</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>LNG-IUS group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intervention LNG IUS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DMPA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three intervention DmPA 12 wk apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LNG-IUS</intervention_name>
    <arm_group_label>LNG-IUS group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DMPA</intervention_name>
    <arm_group_label>DMPA group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female age 18-45 yr&#xD;
&#xD;
          -  Moderate to severe pelvic pain categorized by VAS &gt;50&#xD;
&#xD;
          -  Previous sexual intercourse&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Co-existing other genital tract disease associated pain&#xD;
&#xD;
          -  Previous hormonal use within 3 months&#xD;
&#xD;
          -  History of DMPA treatment failure&#xD;
&#xD;
          -  WHO eligibility criteria 2009 for DMPA and LNG-IUS Category 3,4&#xD;
&#xD;
          -  Fertility desire in upcoming 1 year&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>King Chulalongkorn Memmorial hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>August 19, 2015</study_first_submitted>
  <study_first_submitted_qc>August 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2015</study_first_posted>
  <last_update_submitted>March 16, 2017</last_update_submitted>
  <last_update_submitted_qc>March 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King Chulalongkorn Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Kamolrat Daoudom</investigator_full_name>
    <investigator_title>Effectiveness of levonorgestrel-intrauterine system (LNG-IUS) versus depot medroxyprogesterone acetate (DMPA) in treatment of pelvic pain in clinically diagnosed endometriotic patients</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
    <mesh_term>Pelvic Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

